Source Fact: Financial Supervisory Service DART / 2026-03-25
Disclosure Type: Material Management Matters Related to Investment Decisions
💡 3-Second Summary
Alteogen has entered into a massive exclusive license agreement worth up to USD 579M (approx. KRW 867.5B) with global biopharma giant ‘Biogen’ to develop subcutaneous (SC) formulations for two drug products using its proprietary ALT-B4 platform.
📊 1. [Key Disclosure Details & Figures Summary]
- Counterparty: Biogen International GMBH (Switzerland-based subsidiary of Biogen Inc., a U.S. global pharmaceutical powerhouse with FY2025 revenue of USD 9,891M / approx. KRW 14.8T)
- Licensed Technology: Recombinant human hyaluronidase (ALT-B4) based on the Hybrozyme platform
- Scope of Agreement: Worldwide exclusive license for the development and commercialization of subcutaneous (SC) injection formulations for two Biogen biologic products utilizing ALT-B4.
- Total Contract Value (Excluding Royalties): Up to USD 579,000,000 (Approx. KRW 867.5B)
- Upfront Payment: USD 20,000,000 (Approx. KRW 30.0B, to be received within 10 business days)
- Additional Product Fee: USD 10,000,000 (Approx. KRW 15.0B) upon the selection and designation of the second product
- Milestones: Up to USD 549,000,000 (Approx. KRW 822.6B) contingent upon successful clinical, regulatory, and commercial achievements for the ALT-B4 applied products.
- Running Royalty: Separate payments based on a specific percentage of net sales after the first commercial sale of the products.
- Key Provisions & Options: Biogen holds an option to add one more product to the development scope, which would further increase the total contract value. All upfront and milestone payments received under this agreement are non-refundable.
- FX Rate Applied: KRW 1,498.30 / USD (As disclosed by the Seoul Foreign Exchange Brokerage on March 25, 2026).
📈 2. [Expert Insight: Stock Price Impact Analysis]
- Validation of Platform Expansion Capacity: Securing Biogen—a dominant leader in neurology and multi-sclerosis therapeutics—as a new partner alongside MSD (Merck) proves that Alteogen’s ALT-B4 has become an essential, industry-standard tool for SC formulation transition. This heavily reinforces the company’s Fundamental valuation.
- Immediate Financial and Profitability Boost: The non-refundable upfront payment of KRW 30.0B will be wired within 10 business days. Given that tech-licensing business models incur minimal cost of goods sold, this cash inflow will instantly flow into operating profit for H1 2026, triggering an immediate earnings surprise.
- Continuous Milestone Momentum Loading: This deal establishes a robust mid-to-long-term valuation pipeline. As Biogen moves through clinical trials toward commercialization, unlocking the USD 549M milestone framework will continuously refresh bullish catalysts for the stock. This disclosure solidifies Alteogen’s position as the undisputed leader of the Korean biotech sector.
📝 Editor’s Comment (by K-STOCK Editor)
The mega-scale tech export jackpot that global market bulls have been starving for is finally locked in! We are talking about Biogen, a massive global titan pulling in nearly KRW 15T in annual revenue. Securing a clean, non-refundable KRW 30.0B upfront check within 10 days, with the contract scale scaling up to KRW 867.5B, is a massive victory. Running royalties are on top of that. Now that Alteogen has mathematically proven that its platform technology is a highly sought-after asset among global big pharma, this disclosure will act as a high-octane engine accelerating a broader biotech rally across the entire Kosdaq market!
📢 Disclaimer & Source Information
Source: This content was structured and generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!